Oncolytics is currently focused on immunotherapy combinations, including our studies with Bavencio®, Keytruda®, Opdivo® and Tecentriq®.
Our clinical development plan is based on pelareorep’s broad applicability to boost the effectiveness of a range of immunotherapies – with an immediate focus on checkpoint inhibitors – across multiple cancer indications. The primary objective is to obtain regulatory approval for pelareorep as quickly as possible and is based on our compelling metastatic breast cancer survival data, our synergies with checkpoint approved inhibitors and our biomarker. The second objective is to expand pelareorep into commercially valuable new treatment areas including other immunotherapy agents in collaboration with pharmaceutical partners.
We are excited to work with Pfizer, Merck KGaA, Merck, Bristol-Myers Squibb and Roche with their checkpoint inhibitors, and look forward to developing our programs to evaluate the efficacy and safety in our clinical studies targeting metastatic breast cancer, early stage breast cancer, multiple myeloma and pancreatic cancer. There is great potential to eventually work with additional immunotherapies in additional indications and this will only drive the potential for treatment with pelareorep.